PA
NVO

Parallel Advisors’s Novo Nordisk NVO Stock Holding History

Parallel Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.05M Buy
55,856
+12,138
+28% +$575K 0.04% 293
2025
Q4 		$2.22M Sell
43,718
-2,142
-5% -$110K 0.04% 272
2025
Q3 		$2.54M Buy
45,860
+1,125
+3% +$65.9K 0.05% 240
2025
Q2 		$3.09M Sell
44,735
-3,436
-7% -$234K 0.06% 207
2025
Q1 		$3.35M Buy
48,171
+52
+0.1% +$4.29K 0.08% 184
2024
Q4 		$4.14M Sell
48,119
-3,268
-6% -$353K 0.09% 164
2024
Q3 		$6.12M Buy
51,387
+124
+0.2% +$16.5K 0.14% 122
2024
Q2 		$7.32M Buy
51,263
+55
+0.1% +$7.29K 0.19% 97
2024
Q1 		$6.58M Buy
51,208
+8,823
+21% +$1.05M 0.18% 102
2023
Q4 		$4.38M Buy
42,385
+1,568
+4% +$155K 0.13% 122
2023
Q3 		$3.71M Buy
40,817
+497
+1% +$43.8K 0.12% 134
2023
Q2 		$3.26M Buy
40,320
+1,758
+5% +$144K 0.11% 153
2023
Q1 		$3.07M Buy
38,562
+12,728
+49% +$903K 0.1% 159
2022
Q4 		$1.75M Sell
25,834
-930
-3% -$54.5K 0.08% 175
2022
Q3 		$1.33M Sell
26,764
-504
-2% -$27K 0.06% 196
2022
Q2 		$1.52M Buy
27,268
+416
+2% +$23.1K 0.07% 176
2022
Q1 		$1.51M Buy
26,852
+2,370
+10% +$122K 0.06% 207
2021
Q4 		$1.37M Buy
24,482
+1,164
+5% +$63.1K 0.05% 220
2021
Q3 		$1.12M Sell
23,318
-1,642
-7% -$79.4K 0.05% 242
2021
Q2 		$1.04M Buy
24,960
+1,626
+7% +$63K 0.04% 247
2021
Q1 		$787K Buy
23,334
+672
+3% +$23.9K 0.04% 268
2020
Q4 		$791K Buy
22,662
+6,178
+37% +$214K 0.04% 246
2020
Q3 		$572K Buy
16,484
+2,634
+19% +$87.8K 0.04% 277
2020
Q2 		$453K Buy
13,850
+938
+7% +$29.9K 0.03% 316
2020
Q1 		$388K Buy
12,912
+168
+1% +$5K 0.03% 304
2019
Q4 		$369K Buy
12,744
+512
+4% +$14.2K 0.03% 354
2019
Q3 		$316K Sell
12,232
-412
-3% -$10.4K 0.03% 366
2019
Q2 		$323K Sell
12,644
-146
-1% -$3.61K 0.03% 329
2019
Q1 		$335K Buy
12,790
+1,560
+14% +$38.3K 0.04% 293
2018
Q4 		$258K Buy
11,230
+64
+0.6% +$1.42K 0.04% 310
2018
Q3 		$263K Sell
11,166
-56
-0.5% -$1.37K 0.03% 321
2018
Q2 		$258K Buy
11,222
+840
+8% +$20K 0.04% 291
2018
Q1 		$256K Sell
10,382
-272
-3% -$7.14K 0.04% 278
2017
Q4 		$286K Buy
10,654
+234
+2% +$5.95K 0.05% 257
2017
Q3 		$259K Buy
10,420
+2,204
+27% +$49.8K 0.04% 274
2017
Q2 		$174K Buy
8,216
+2,528
+44% +$51K 0.03% 343
2017
Q1 		$117K Buy
5,688
+3,106
+120% +$54.1K 0.02% 407
2016
Q4 		$46K Buy
+2,582
New +$46.8K 0.01% 616

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Parallel Advisors's NVO Position: Q1 2026 in Review

Parallel Advisors increased its Novo Nordisk (NVO) stake by 28% in Q1 2026, buying an estimated $575K and bringing the position to 55,856 shares worth $2.05M. The position accounts for 0.04% of the portfolio, ranked #293.

Parallel Advisors first reported a position in NVO in Q4 2016 and has held it in 38 quarters since. The position peaked at $7.32M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Parallel Advisors held 55,856 shares of Novo Nordisk worth $2.05M as of Q1 2026.
  • Parallel Advisors bought 12,138 Novo Nordisk shares in Q1 2026, an estimated $575K.
  • Novo Nordisk made up 0.04% of Parallel Advisors's portfolio in Q1 2026, its #293 holding.
  • Parallel Advisors first reported a position in Novo Nordisk in Q4 2016 and has held it in 38 quarters since.
  • Parallel Advisors's Novo Nordisk position peaked at $7.32M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.